Sei Investments CO I Mab Transaction History

Sei Investments CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $8,203 - $18,282	992 Added 8.12%	13,207 $149,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $89,673 - $335,596	7,151 Added 141.21%	12,215 $198,000
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $69,645 - $102,835	-1,218 Reduced 19.39%	5,064 $367,000
Q2 2021 Aug 06, 2021	BUY	$47.86 - $83.95 $300,656 - $527,373	6,282 New	6,282 $527,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.